Hongli Group Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HLP research report →
Price Chart
About the company
Hongli Group Inc. , through its affiliated entities, specializes in the engineering, tailoring, production, and distribution of cold roll-formed steel profiles. These precision components are utilized in a variety of machinery and equipment, with a market reach that extends across the People's Republic of China, South Korea, Japan, the United States, and Sweden.
- CEO
- Jie Liu
- IPO
- 2023
- Employees
- 167
- HQ
- Weifang, SD, CN
Get TickerSpark's AI analysis on HLP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $185.35M
- P/E
- 93.58
- PEG
- 0.31
- P/S
- 9.46
- P/B
- 3.14
- EV/EBITDA
- 60.10
- Div Yield
- 0.00%
- Gross Margin
- 32.54%
- Op Margin
- 12.41%
- Net Margin
- 9.91%
- ROE
- 3.43%
- ROIC
- 3.14%
Latest fiscal year · YoY change
- Revenue
- $19.60M+39.0%
- Gross Profit
- $6.38M+41.1%
- Op Income
- $2.43M
- Net Income
- $1.94M+203.3%
- EPS
- $0.03+203.5%
- OCF Growth
- +312.1%
- FCF Growth
- +248.0%
- 52W High
- $2.62
- 52W Low
- $0.34
- 50D MA
- $1.56
- 200D MA
- $1.06
- Beta
- 0.49
- RSI (14)
- 79
- Avg Volume
- 152.09K
No earnings-call transcripts are available for HLP yet.
- Free Float
- 67.3%
- Shares Outstanding
- 74.74M
- Float Shares
- 50.30M
Our HLP coverage
Recent articles, reports, and earnings notes.
No research on HLP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HLP report →Hongli Group Inc. Announces Appointment of Mr. Michael W.
prnewswire.com · Oct 5
Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression
marketbeat.com · Sep 24
Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026
globenewswire.com · Sep 21
Helus Pharma: An Undervalued Psychedelic Platform Approaching A Major Catalyst
seekingalpha.com · Aug 21
Hongli Group Inc. Announces Compliance with Nasdaq Minimum Bid Price Requirement
prnewswire.com · Aug 12
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
globenewswire.com · Jul 21
Helus Pharma: APPROACHing Inflection: Pivotal Readout Sets Up Asymmetric Upside
seekingalpha.com · Jul 12
Hongli Group Inc. Receives Nasdaq Notice Regarding Minimum Bid Price Deficiency
prnewswire.com · Jul 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.